Startups
Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 17, 2025 | Seasoned leaders step into key roles at life sciences startups | Melodia Therapeutics, a Forty51 Ventures company, developing a next generation DPP1 inhibitor with best-in-class potential for inflammatory conditions, has appointed Jonathan Talbot as Chief Executive Officer. He brings over 15 years of in... |
| Jun 24, 2024 | Melodia Therapeutics launched with in-licensing deal | MDI-0151 is a clinical candidate compound from the Alivexis’ discovery program MOD-A, focused on Cathepsin C inhibition. Cathepsin C is an enzyme responsible for the activation of a group of proteases that play an important role in the des... |
Reviews 0
FAQ about Melodia Therapeutics
What has the press written about Melodia Therapeutics?
Parsers VC has collected 3 articles mentioning Melodia Therapeutics, among them “Seasoned leaders step into key roles at life sciences startups” (Sep 17, 2025) and “Melodia Therapeutics launched with in-licensing deal” (Jun 24, 2024).
Is Melodia Therapeutics still active?
Yes, Melodia Therapeutics is active; its latest activity on Parsers VC dates from Sep 21, 2026.